Metrics as of 10/16/2026, 04:39 PM (Berlin time), refresh in progress.
Longeveron Stock
Longeveron Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Stephen H. Willard
- Employees
- 38
- Market cap
- $4 M
- IPO
- 12/02/2021
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a…
Longeveron stock: price history
1D
-6.7%
1W
-43.5%
1M
-79.0%
6M
-87.3%
YTD
-72.3%
1Y
-83.1%
2Y
-93.0%
5Y
-99.6%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~2% weaker price swings than usual
Ask the agents about Longeveron
Analyst assessment of Longeveron
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
3
BUY
1
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 11/05/2026
Longeveron stock metrics
P/E
-0.14
P/B
0.43
EV/EBITDA
0.23
RETURN ON EQUITY
-58.4%
NET MARGIN
-2,116.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.8%
FLOAT SHARES
2,489,569
AVG. DAILY VOLUME (30D)
145,787
Insider transactions (SEC)
Jhaveri Nirav S.
Willard Stephen H
Agafonova Nataliya
Lehr Paul T
Blass Devin
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Longeveron stock
What does Longeveron do?
Longeveron Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Stephen H. Willard, the company employs around 38 people.
The IPO was on 12/02/2021; the stock trades on NASDAQ under the ticker LGVN.
What do analysts say about Longeveron stock?
4 analysts rate the stock, the consensus is Buy (as of 11/05/2026).
The average price target is US$10.00, ranging from US$10.00 to US$10.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Longeveron report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -2% stronger than usual.
Does Longeveron pay a dividend?
No, Longeveron currently does not pay a dividend.
Which stocks are comparable to Longeveron?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Longeveron stock analyzed?
Clicking "Analyze stock" lets five strategies assess Longeveron against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.